The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
- PMID: 35128204
- PMCID: PMC8807853
- DOI: 10.1016/j.jacbts.2021.11.010
The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
Keywords: cardiac dysfunction; cardiotoxicity; doxorubicin; heart failure; paraoxonase-1.
Conflict of interest statement
Dr Ibanez is supported by the European Commission (H2020-HEALTH grant Nº 945118 and ERC-CoG grant Nº 819775) and by the Spanish Ministry of Science and Innovation (MCN; ‘RETOS 2019’ grant Nº PID2019-107332RB-I00). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation, and is a Center of Excellence Severo Ochoa. Dr Moreno-Arciniegas has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
- doi: 10.1016/j.jacbts.2021.10.010
References
-
- Lopez-Sendon J., Alvarez-Ortega C., Zamora Aunon P., et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41:1720–1729. - PubMed
-
- Galan-Arriola C., Lobo M., Vilchez-Tschischke J.P., et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73(7):779–791. - PubMed
-
- Martin-Garcia A., Diaz-Pelaez E., Lopez-Corral L., et al. T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer. J Am Coll Cardiol Img. 2020;13(7):1630–1632. - PubMed
Publication types
LinkOut - more resources
Full Text Sources